NCT04288232View on ClinicalTrials.gov

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 16, 2017

Study Completion Date

November 16, 2017

Conditions
Center-involved Diabetic Macular Edema
Interventions
DRUG

Aflibercept Injection [Eylea]

Intravitreal aflibercept Injection 2.0mg/0.05 ml

All Listed Sponsors
collaborator

Kaohsiung Veterans General Hospital.

OTHER

collaborator

National Taiwan University Hospital

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

NCT04288232 - Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan | Biotech Hunter | Biotech Hunter